Get the Stockscreener App
1.64
4.46%
0.07
After Hours:
1.64
Bioatla Inc stock is traded at $1.64, with a volume of 301.86K.
It is up +4.46% in the last 24 hours and down -17.59% over the past month.
BioAtla Inc is a clinical-stage biopharmaceutical company. The company is engaged in the development of a novel class of specific and selective antibody-based therapeutics for the treatment of solid tumor cancer. Its pipeline products comprise mecbotamab vedotin (BA3011), ozuriftamab vedotin (BA3021), and evalstotug (BA3071), and its Phase 1 clinical trial of BA3182 (CAB-EpCAM x CAB-CD3) and Bispecific antibody programs.
See More
Previous Close:
$1.57
Open:
$1.6
24h Volume:
301.86K
Relative Volume:
0.26
Market Cap:
$78.80M
Revenue:
-
Net Income/Loss:
$-123.46M
P/E Ratio:
-0.6309
EPS:
-2.5993
Net Cash Flow:
$-104.11M
1W Performance:
+10.81%
1M Performance:
-17.59%
6M Performance:
-4.09%
1Y Performance:
+11.56%
1-Day Range:
$1.57
$1.67
1-Week Range:
$1.33
$1.90
52-Week Range:
$1.14
$4.02
Bioatla Inc Stock (BCAB) Company Profile
Name
Bioatla Inc
Sector
Industry
Phone
858-558-0708
Address
11085 TORREYANA ROAD, SAN DIEGO
Compare BCAB with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
BCAB
Bioatla Inc
|
1.64 | 78.80M | 0 | -123.46M | -104.11M | -2.5993 |
|
VRTX
Vertex Pharmaceuticals Inc
|
464.56 | 119.70B | 10.63B | -479.80M | -1.35B | 13.33 |
|
REGN
Regeneron Pharmaceuticals Inc
|
754.87 | 82.75B | 13.85B | 4.65B | 3.32B | 35.06 |
|
ARGX
Argen X Se Adr
|
614.59 | 36.73B | 1.86B | -40.29M | -1.28B | -4.16 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
253.74 | 32.53B | 2.09B | -332.26M | 16.06M | -4.14 |
|
BNTX
Biontech Se Adr
|
120.72 | 28.50B | 3.30B | -501.07M | 1.03B | 11.54 |
Bioatla Inc Stock (BCAB) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Nov-13-24 | Downgrade | H.C. Wainwright | Buy → Neutral |
| Sep-15-22 | Initiated | JMP Securities | Mkt Outperform |
| May-05-22 | Downgrade | Credit Suisse | Outperform → Neutral |
| Mar-21-22 | Initiated | H.C. Wainwright | Buy |
| Oct-15-21 | Resumed | BTIG Research | Buy |
| Jun-28-21 | Initiated | ROTH Capital | Buy |
| May-05-21 | Resumed | Credit Suisse | Outperform |
| Apr-26-21 | Resumed | Credit Suisse | Outperform |
| Jan-11-21 | Initiated | BTIG Research | Buy |
| Jan-11-21 | Initiated | Credit Suisse | Outperform |
| Jan-11-21 | Initiated | JP Morgan | Overweight |
| Jan-11-21 | Initiated | Jefferies | Buy |
View All
Bioatla Inc Stock (BCAB) Latest News
BioAtla's SWOT analysis: oncology biotech stock faces pivotal year - Investing.com
BioAtla's SWOT analysis: oncology biotech stock faces pivotal year By Investing.com - Investing.com Canada
BioAtla, Inc. (NASDAQ:BCAB) Q3 2024 Earnings Call Transcript - MSN
GSA Capital Partners LLP Purchases New Position in BioAtla, Inc. (NASDAQ:BCAB) - MarketBeat
BioAtla, Inc. (NASDAQ:BCAB) Sees Significant Drop in Short Interest - MarketBeat
Michael Burry's Scion fund exits BioAtla, boosts Alibaba stake, adds puts: top Q3 trades - MSN
HC Wainwright Weighs in on BioAtla FY2024 Earnings - Defense World
FY2024 Earnings Estimate for BioAtla Issued By HC Wainwright - MarketBeat
BioAtla (NASDAQ:BCAB) Rating Lowered to Neutral at HC Wainwright - Defense World
Analysis of TANG CAPITAL MANAGEMENT LLC's Recent Transaction in BioAtla Inc - GuruFocus.com
Michael Burry's Scion fund exits BioAtla, boosts Alibaba stake, adds puts: top Q3 trades (HPP:NYSE) - Seeking Alpha
HC Wainwright & Co. Downgrades BioAtla (BCAB) - MSN
BioAtla (NASDAQ:BCAB) Downgraded to "Neutral" Rating by HC Wainwright - MarketBeat
BioAtla Inc (BCAB) Q3 2024 Earnings Call Highlights: Strategic Advances Amid Financial Challenges By GuruFocus - Investing.com Canada
Head to Head Review: Alector (NASDAQ:ALEC) vs. BioAtla (NASDAQ:BCAB) - Defense World
3 Promising US Penny Stocks With At Least $90M Market Cap - Simply Wall St
BioAtla Reports Q3 2024 Financial Results and Clinical Advances - TipRanks
BioAtla reports Q3 EPS (22c), consensus (36c) - TipRanks
BioAtla Reports Third Quarter 2024 Financial Results and Highlights Recent Progress - StockTitan
BioAtla (BCAB) Scheduled to Post Earnings on Thursday - MarketBeat
BioAtla to Announce Third Quarter 2024 Financial Results and Provide Business Highlights on November 7, 2024 - The Manila Times
BioAtla, Inc. (NASDAQ:BCAB) has caught the attention of institutional investors who hold a sizeable 39% stake - Yahoo Finance UK
BioAtla, Inc. (NASDAQ:BCAB) Short Interest Update - MarketBeat
BioAtla, Inc. (BCAB): Among Michael Burry’s Top 10 Stock Picks Heading Into 2025 - Insider Monkey
You might want to take a look at BioAtla Inc (BCAB) now - SETE News
BioAtla Inc (BCAB) stock: A year of ups and downs - US Post News
Market Insights: BioAtla Inc (BCAB)’s Notable Gain of 7.25, Closing at 2.07 - The Dwinnex
Michael Burry – Top 10 Holdings – Latest 13F - The Acquirer's Multiple
636,136 Shares in BioAtla, Inc. (NASDAQ:BCAB) Acquired by AQR Capital Management LLC - Defense World
AQR Capital Management LLC Makes New Investment in BioAtla, Inc. (NASDAQ:BCAB) - MarketBeat
There is no doubt that BioAtla Inc (BCAB) ticks all the boxes. - SETE News
Bank of Montreal Can Buys 143,521 Shares of BioAtla, Inc. (NASDAQ:BCAB) - Defense World
'Big Short' Investor Michael Burry's China Bet Pays Off As Top Picks Surge Nearly 60% In 2 Months - Benzinga
BioAtla's FDA Fast-Tracked Drug Candidate Boosts Its Oncology Prospects, Speculative Buy - Seeking Alpha
Renaissance Technologies LLC Sells 370,800 Shares of BioAtla, Inc. (NASDAQ:BCAB) - MarketBeat
BioAtla: Numerous Catalysts Coming In Q4 (NASDAQ:BCAB) - Seeking Alpha
Analyzing the Impact of Earnings Reports on BioAtla Inc Inc. (BCAB) Price Performance - The InvestChronicle
BioAtla to Score Up to $133M - San Diego Business Journal
Should investors be concerned about BioAtla Inc (BCAB)? - US Post News
BioAtla to Host Virtual R&D Day on Clinical Program and Pipeline Updates on July 25, 2024 - Quantisnow
BioAtla Announces Upcoming Poster Presentation at the 39th Society for Immunotherapy of Cancer Annual Meeting - ForexTV.com
Pleasing Signs As A Number Of Insiders Buy BioAtla Stock - Simply Wall St
12 Health Care Stocks Moving In Wednesday's Intraday Session - Benzinga
JMP Securities gives a Mkt outperform recommendation for BioAtla Inc (BCAB) - Knox Daily
Rhumbline Advisers Cuts Stock Position in BioAtla, Inc. (NASDAQ:BCAB) - Defense World
Potential Price Increase for Equinix Inc (EQIX) After Recent Insider Activity - Knox Daily
BCAB’s Market Quandary: Decoding the Ups and Downs of 2023 - The InvestChronicle
Analyzing BCAB’s price-to-book ratio for the last quarter - US Post News
Michael Burry buys 634,000 shares of this $1 penny stockFinbold - Finbold - Finance in Bold
BioAtla Announces Upcoming Oral Presentation at the Society for Melanoma Research 21st International Congress - The Manila Times
BioAtla Inc (BCAB)’s financial ratios: A comprehensive overview - The Dwinnex
Bioatla Inc Stock (BCAB) Financials Data
Revenue
Net Income
Cash Flow
EPS
Bioatla Inc Stock (BCAB) Insider Trading
| Insider Trading | Relationship | Date | Transaction | Cost | #Shares | Value ($) | #Shares Total |
|---|---|---|---|---|---|---|---|
| SHORT JAY M PHD | Chief Executive Officer |
Dec 20 '23 |
Buy |
2.14 |
50,000 |
106,910 |
1,439,283 |
| STEINMAN LAWRENCE | Director |
Dec 19 '23 |
Buy |
2.05 |
20,000 |
41,048 |
38,459 |
| Vasquez Christian | See Remarks |
Dec 19 '23 |
Buy |
2.04 |
7,495 |
15,262 |
115,659 |
1.35%
0.87%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):